Clinical Trials
349
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (246 trials with phase data)• Click on a phase to view related trials
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
- Conditions
- Erythrodermic PsoriasisGeneralized Pustular Psoriasis
- Interventions
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2025-10-10
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 19
- Registration Number
- NCT06295692
- Locations
- 🇯🇵
JR Sapporo Hospital, Hokkaido, Japan
🇯🇵Ichinomiya Municipal Hospital, Ichinomiya, Japan
🇯🇵Teikyo University Hospital, Itabashi Ku, Japan
A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
- Conditions
- Retinitis Pigmentosa
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2025-10-21
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 4
- Registration Number
- NCT05926583
- Locations
- 🇯🇵
National Hospital Organization Tokyo Medical Center, Meguro-ku, Japan
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
- Conditions
- Urinary Bladder NeoplasmsReceptors, Fibroblast Growth Factor
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2025-10-10
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 5
- Registration Number
- NCT05567185
- Locations
- 🇯🇵
St Marianna University Hospital, Kanagawa, Japan
🇯🇵Osaka International Cancer Institute, Osaka, Japan
🇯🇵Toyama University Hospital, Toyama, Japan
A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants
- Conditions
- Respiratory Syncytial Virus Prevention
- Interventions
- Biological: Ad26/protein preF RSV VaccineOther: Placebo
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 2192
- Registration Number
- NCT05242432
- Locations
- 🇯🇵
Shohokai Toda Internal Medicine and Neurology Clinic, Akashi-shi, Japan
🇯🇵Medical Corporation JR Hiroshima Hospital, Hiroshima-shi, Japan
🇯🇵Seikokai Omi Medical Center, Kusatsu-shi, Japan
A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2025-10-21
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 7
- Registration Number
- NCT05167825
- Locations
- 🇯🇵
Nagano Children's Hospital, Azumino-shi, Japan
🇯🇵Institute of Science Tokyo Hospital, Bunkyō City, Japan
🇯🇵Fukuoka Children's Hospital, Fukuoka, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- 26
- Next